Fibrinolytic drugs induced hemorrhage: mechanisms and solutions.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
medline:
12
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
ppublish
Résumé
Thrombosis has been emerging as a major global life-threatening issue with high mortality and serious complications, especially in the post-COVID-19 era. Compared with the commonly used plasminogen activators thrombolytic drugs, fibrinolytic drugs are no longer heavily dependent on the patients' own plasminogen, which are poorly expressed in most patients. As a novel "direct acting" thrombolytic agent, fibrinolytic drugs are considered to have stronger thrombolytic efficacy and safety than the widely used plasminogen activators. However, the risk of their hemorrhage remains a major concern. Herein, the molecular mechanisms and solutions were summarized for the first time based on the systematic review of the latest developments, which could shed new light on the development of novel safety fibrinolytic drugs in the future.
Identifiants
pubmed: 37395191
doi: 10.1097/MBC.0000000000001231
pii: 00001721-990000000-00082
doi:
Substances chimiques
Fibrinolytic Agents
0
Plasminogen Activators
EC 3.4.21.-
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-271Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Sweid A, Hammoud B, Weinberg JH, Oneissi M, Raz E, Shapiro M, et al. Letter: thrombotic neurovascular disease in COVID-19 patients. Neurosurgery 2020; 87:E400–E406.
George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:654–666.
Kluft C, Sidelmann JJ, Gram JB. Assessing safety of thrombolytic therapy. Semin Thromb Hemost 2017; 43:300–310.
Swan D, Loughran N, Makris M, Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy. Blood Rev 2020; 39:100619.
Nan D, Jin H, Yang D, Yu W, Jia J, Yu Z, et al. Combination of polyethylene glycol-conjugated urokinase nanogels and urokinase for acute ischemic stroke therapeutic implications. Transl Stroke Res 2021; 12:844–857.
Zhu J, Wan Y, Xu H, Wu Y, Hu B, Jin H. The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe? Cell Mol Life Sci 2019; 76:1489–1506.
Kazemi F, Arab SS, Mohajel N, Keramati M, Niknam N, Aslani MM, et al. Computational simulations assessment of mutations impact on streptokinase (SK) from a Group G Streptococci with enhanced activity: insights into the functional roles of structural dynamics flexibility of SK and stabilization of SK-Μplasmin catalytic complex. J Biomol Struct Dyn 2019; 37:1944–1955.
Fang M-J, Qi C-Y, Chen X-Y, Hu P-Y, Wang J-W, Xu P-F, et al. Effects of batroxobin treatment on the survival of random skin flaps in rats. Int Immunopharmacol 2019; 72:235–242.
Guo Y, Zuo Y, Wang Q, Tang B, Li F, Sun Y. Meta-analysis of defibrase in treatment of acute cerebral infarction. Chin Med J (Engl) 2006; 119:662–668.
Gasmi A, Chabchoub A, Guermazi S, Karoui H, Elayeb M, Dellagi K. Further characterization and thrombolytic activity in a rat model of a fibrinogenase from vipera lebetina venom. Thromb Res 1997; 86:233–242.
Di Minno G, Margaglione M, Cerbone AM, Papa R, Mattei A. Newer agents for coronary thrombolysis. Perspectives from clinical studies. Pharmacol Res 1989; 21:153–161.
Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol 2019; 4:747–755.
Miles LA, Ny L, Wilczynska M, Shen Y, Ny T, Parmer RJ. Plasminogen receptors and fibrinolysis. IJMS 2021; 22:1712.
Sun Z, Zhang P-X, Wang P, Gurewich V, Shen H-Y, Liu J-N. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation. Thromb Res 2002; 106:105–111.
Dunn FW, Deguchi K, Soria J, Soria C, Lijnen HR, Tobelem G, et al. Importance of the interaction between plasminogen and fibrin for plasminogen activation by tissue-type plasminogen activator. Thromb Res 1984; 36:345–351.
Kotb E. Activity assessment of microbial fibrinolytic enzymes. Appl Microbiol Biotechnol 2013; 97:6647–6665.
Barzkar N, Jahromi ST, Vianello F. Marine microbial fibrinolytic enzymes: an overview of source, production, biochemical properties and thrombolytic activity. Marine Drugs 2022; 20:46.
Gao S, Silasi-Mansat R, Behar AR, Lupu F, Griffin CT. Excessive plasmin compromises hepatic sinusoidal vascular integrity after acetaminophen overdose. Hepatology 2018; 68:1991–2003.
Marder VJ. Thrombolytic therapy for deep vein thrombosis: potential application of plasmin. Thromb Res 2009; 123:S56–S61.
Novokhatny VV, Jesmok GJ, Landskroner KA, Marder VJ, Zimmerman TP. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis? Trends Pharmacol Sci 2004; 25:72–75.
Baharifar H, Khoobi M, Arbabi Bidgoli S, Amani A. Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme. Int J Biol Macromol 2020; 143:181–189.
Zhang N, Li C, Zhou D, Ding C, Jin Y, Tian Q, et al. Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis. Acta Biomater 2018; 70:227–236.
Qi F, Hu C, Yu W, Hu T. Conjugation with eight-arm PEG markedly improves the in vitro activity and prolongs the blood circulation of staphylokinase. Bioconjug Chem 2018; 29:451–458.
Wang Y, Wang H, Zhang Y, Xu F, Wang J, Zhang F. Stepwise strategy to identify thrombin as a hydrolytic substrate for nattokinase. J Chem Inf Model 2022; 62:5780–5793.
Ichinose A, Takio K, Fujikawa K. Localization of the binding site of tissue-type plasminogen activator to fibrin. J Clin Invest 1986; 78:163–169.
LeCouffe NE, Kappelhof M, Treurniet KM, Rinkel LA, Bruggeman AE, Berkhemer OA, et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke. N Engl J Med 2021; 385:1833–1844.
Diaz A, Merino P, Manrique LG, Cheng L, Yepes M. Urokinase-type plasminogen activator (UPA) protects the tripartite synapse in the ischemic brain via ezrin-mediated formation of peripheral astrocytic processes. J Cereb Blood Flow Metab 2019; 39:2157–2171.
Chen S, Chen D, Liu Y, Xu Y, Lin H, Cheng Y, et al. Enhanced clot lysis by a single point mutation in a reteplase variant. Br J Haematol 2022; 196:1076–1085.
Warach SJ, Dula AN, Milling TJ. Tenecteplase thrombolysis for acute ischemic stroke. Stroke 2020; 51:3440–3451.
Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8:141–150.
Song H, Wang Y, Ma Q, Chen H, Liu B, Yang Y, et al. Efficacy and safety of recombinant human prourokinase in acute ischemic stroke: a phase IIa randomized clinical trial. Transl Stroke Res 2022; 13:995–1004.
Held PH, Teo KK, Yusuf S. Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction. Circulation 1990; 82:1668–1674.
Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976–1976.
Kurihara H, Matsumoto S, Tamura R, Yachiku K, Nakata A, Nakagawa T, Yoshino T, et al. Clinical outcome of percutaneous coronary intervention with antecedent mutant T-PA administration for acute myocardial infarction. Am Heart J 2004; 147:E14.
Bhana N, Spencer CM. Lanoteplase. BioDrugs 2000; 13:217–224.
Oikawa K, Kamimura H, Watanabe T, Miyamoto I, Higuchi S. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb Res 2001; 101:493–500.
Rijken D, Barrett-Bergshoeff M, Jie AFH, Criscuoli M, Sakharov D. Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2tu-PA). Thromb Haemost 2004; 91:52–60.
Ding J, Pan L, Hu Y, Rajah GB, Zhou D, Bai C, et al. Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: a real-world experience. CNS Neurosci Ther 2019; 25:638–646.
Bourgain RH, Six F. The effect of defibrase on arterial thrombus formation. Thromb Res 1975; 6:195–200.
Ouyang C, Huang T-F. The properties of the purified fibrinolytic principle from agkistrodon acutus snake venom. Toxicon 1977; 15:161–166.
Markland FS, Swenson S. Snake venom metalloproteinases. Toxicon 2013; 62:3–18.
Casewell NR, Wüster W, Vonk FJ, Harrison RA, Fry BG. Complex cocktails: the evolutionary novelty of venoms. Trends Ecol Evol 2013; 28:219–229.
Tasoulis T, Pukala TL, Isbister GK. Investigating toxin diversity and abundance in snake venom proteomes. Front Pharmacol 2022; 12:768015.
Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM, Diener H-C, Howard G, et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the Ancrod Stroke Program. Stroke 2009; 40:3796–3803.
Ding J, Zhou D, Hu Y, Elmadhoun O, Pan L, Ya J, et al. The efficacy and safety of batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis. J Thromb Thrombolysis 2018; 46:371–378.
Guo Y, Wang L, Tang B, Li F, Wang Q. Dynamic changes in fibrinogen levels of patients with acute cerebral infarction after taking defibrase. Neural Regen Res 2008; 3:513–516.
BAI L, GU P. Establishment and application of evaluation standard for rational use of fibrinogenase injection. J China Presc Drug 2021; 19:74–76.
Marchand M, Monnot C, Muller L, Germain S. Extracellular matrix scaffolding in angiogenesis and capillary homeostasis. Semin Cell Dev Biol 2019; 89:147–156.
Casino P, Gozalbo-Rovira R, Rodríguez-Díaz J, Banerjee S, Boutaud A, Rubio V, et al. Structures of collagen IV globular domains: insight into associated pathologies, folding and network assembly. Corrigendum. IUCrJ 2020; 7:777–1777.
Baramova EN, Shannon JD, Bjarnason JB, Fox JW. Degradation of extracellular matrix proteins by hemorrhagic metalloproteinases. Arch Biochem Biophys 1989; 275:63–71.
Ghezellou P, Dillenberger M, Kazemi SM, Jestrzemski D, Hellmann B, Spengler B. Comparative venom proteomics of Iranian, Macrovipera Lebetina Cernovi, and Cypriot, Macrovipera Lebetina Lebetina, Giant Vipers. Toxins 2022; 14:716.
Escalante T, Shannon J, Moura-da-Silva AM, María Gutiérrez J, Fox JW. Novel insights into capillary vessel basement membrane damage by snake venom hemorrhagic metalloproteinases: a biochemical and immunohistochemical study. Arch Biochem Biophys 2006; 455:144–153.
Moreira L, Borkow G, Ovadia M, Gutiérrez J. Pathological changes induced by BaH1, a hemorrhagic proteinase isolated from Bothrops Asper (Terciopelo) snake venom, on mouse capillary blood vessels. Toxicon 1994; 32:977–987.
Castro AC, Escalante T, Rucavado A, Gutiérrez JM. Basement membrane degradation and inflammation play a role in the pulmonary hemorrhage induced by a P-III snake venom metalloproteinase. Toxicon 2021; 197:12–23.
Silva de França F, Villas-Boas IM, Cogliati B, Woodruff TM, Reis E, da S, et al. C5a-C5aR1 axis activation drives envenomation immunopathology by the snake Naja Annulifera. Front Immunol 2021; 12:652242.
Escalante T, Rucavado A, Fox JW, Gutiérrez JM. Key events in microvascular damage induced by snake venom hemorrhagic metalloproteinases. J Proteomics 2011; 74:1781–1794.
Herrera C, Escalante T, Voisin M-B, Rucavado A, Morazán D, Macêdo JKA, et al. Tissue localization and extracellular matrix degradation by PI, PII and PIII snake venom metalloproteinases: clues on the mechanisms of venom-induced hemorrhage. PLoS Negl Trop Dis 2015; 9:e0003731.
Gutiérrez JM, Escalante T, Rucavado A, Herrera C. Hemorrhage caused by snake venom metalloproteinases: a journey of discovery and understanding. Toxins (Basel) 2016; 8:93.
Gutiérrez JM, Rucavado A, Escalante T, Díaz C. Hemorrhage induced by snake venom metalloproteinases: biochemical and biophysical mechanisms involved in microvessel damage. Toxicon 2005; 45:997–1011.
Gutiérrez JM, Núñez J, Escalante T, Rucavado A. Blood flow is required for rapid endothelial cell damage induced by a snake venom hemorrhagic metalloproteinase. Microvasc Res 2006; 71:55–63.
Schattner M, Fritzen M, Ventura Jde S, de Albuquerque Modesto JC, Pozner RG, Moura-da-Silva AM, et al. The snake venom metalloproteases berythractivase and jararhagin activate endothelial cells. Biol Chem 2005; 386:369–374.
Ashrafizadeh M, Mohammadinejad R, Tavakol S, Ahmadi Z, Roomiani S, Katebi M. Autophagy, anoikis, ferroptosis, necroptosis, and endoplasmic reticulum stress: potential applications in melanoma therapy. J Cell Physiol 2019; 234:19471–19479.
Díaz C, Valverde L, Brenes O, Rucavado A, Gutiérrez JM. Characterization of events associated with apoptosis/anoikis induced by snake venom metalloproteinase BaP1 on human endothelial cells: metalloproteinase-induced apoptosis/anoikis in endothelial cells. J Cell Biochem 2005; 94:520–528.
Gallagher PG, Bao Y, Serrano SMT, Kamiguti AS, Theakston RD, Fox JW. Use of microarrays for investigating the subtoxic effects of snake venoms: insights into venom-induced apoptosis in human umbilical vein endothelial cells. Toxicon 2003; 41:429–440.
Tanjoni I, Weinlich R, Della-Casa MS, Clissa PB, Saldanha-Gama RF, de Freitas MS, et al. Jararhagin, a snake venom metalloproteinase, induces a specialized form of apoptosis (anoikis) selective to endothelial cells. Apoptosis 2005; 10:851–861.
Araki S, Masuda S, Maeda H, Ying MJ, Hayashi H. Involvement of specific integrins in apoptosis induced by vascular apoptosis-inducing protein 1. Toxicon 2002; 40:535–542.
Wu W. Activation of MMP-2, cleavage of matrix proteins, and adherens junctions during a snake venom metalloproteinase-induced endothelial cell apoptosis. Exp Cell Res 2003; 288:143–157.
Souza DHF, Iemma MRC, Ferreira LL, Faria JP, Oliva MLV, Zingali RB, et al. The disintegrin-like domain of the snake venom metalloprotease alternagin inhibits Α2β1 integrin-mediated cell adhesion. Arch Biochem Biophys 2000; 384:341–350.
Beristain-Covarrubias N, Perez-Toledo M, Thomas MR, Henderson IR, Watson SP, Cunningham AF. Understanding infection-induced thrombosis: lessons learned from animal models. Front Immunol 2019; 10:2569.
König G, Obser T, Marggraf O, Schneppenheim S, Budde U, Schneppenheim R, et al. Alteration in GPIIb/IIIa binding of VWD-associated von Willebrand factor variants with C-terminal missense mutations. Thromb Haemost 2019; 119:1102–1111.
Shen C, Liu M, Tian H, Li J, Xu R, Mwangi J, et al. Conformation-specific blockade of ΑIIbβ3 by a non-RGD peptide to inhibit platelet activation without causing significant bleeding and thrombocytopenia. Thromb Haemost 2020; 120:1432–1441.
Jia Y, Pérez JC. Molecular cloning and characterization of CDNAs encoding metalloproteinases from snake venom glands. Toxicon 2010; 55:462–469.
Serrano SMT, Wang D, Shannon JD, Pinto AFM, Polanowska-Grabowska RK, Fox JW. Interaction of the cysteine-rich domain of snake venom metalloproteinases with the A1 domain of von Willebrand factor promotes site-specific proteolysis of von Willebrand factor and inhibition of von Willebrand factor-mediated platelet aggregation: SVMP interaction with VWA domains. FEBS J 2007; 274:3611–3621.
Seifert SA, Armitage JO, Sanchez EE. Snake envenomation. N Engl J Med 2022; 386:68–78.
Ukken FP, Dowell NL, Hajra M, Carroll SB. A novel broad spectrum venom metalloproteinase autoinhibitor in the rattlesnake Crotalus atrox evolved via a shift in paralog function. Proc Natl Acad Sci U S A 2022; 119:e2214880119.
Lou Z, Hou J, Liang X, Chen J, Qiu P, Liu Y, et al. Crystal structure of a non-hemorrhagic fibrin(ogen)olytic metalloproteinase complexed with a novel natural tri-peptide inhibitor from venom of Agkistrodon acutus. J Struct Biol 2005; 152:195–203.
Yamakawa Y, Omori-Satoh T. Primary structure of the antihemorrhagic factor in serum of the Japanese Habu: a snake venom metalloproteinase inhibitor with a double-headed cystatin domain. J Biochem 1992; 112:583–589.
Qi Z-Q, Yonaha K, Tomihara Y, Toyama S. Characterization of the antihemorrhagic factors of mongoose (Herpestes edwardsii). Toxicon 1994; 32:1459–1469.
Ramos OHP, Selistre-de-Araujo HS. Comparative analysis of the catalytic domain of hemorrhagic and non-hemorrhagic snake venom metallopeptidases using bioinformatic tools. Toxicon 2004; 44:529–538.
García LT, Parreiras e Silva LT, Ramos OHP, Carmona AK, Bersanetti PA, Selistre-de-Araujo HS. The effect of post-translational modifications on the hemorrhagic activity of snake venom metalloproteinases. Comp Biochem Physiol C Toxicol Pharmacol 2004; 138:23–32.
Jeon O-H, Kim D-S. Molecular cloning and functional characterization of a snake venom metalloprotease. Eur J Biochem 1999; 263:526–533.
Abib H, Laraba-Djebari F. Effects of 60 Co gamma radiation on toxicity and hemorrhagic, myonecrotic, and edema-forming activities of Cerastes Cerastes venom. Can J Physiol Pharmacol 2003; 81:1125–1130.
Yao M, Yang Y, Fan J, Ma C, Liu X, Wang Y, et al. Production, purification, and functional properties of microbial fibrinolytic enzymes produced by microorganism obtained from soy-based fermented foods: developments and challenges. Crit Rev Food Sci Nutr 2022; 1–26.
Abdul S, Dekkers DHW, Ariëns RAS, Leebeek FWG, Rijken DC, Uitte de Willige S. On the localization of the cleavage site in human alpha-2-antiplasmin, involved in the generation of the nonplasminogen binding form. J Thromb Haemost 2020; 18:1162–1170.
Kimura M, Andersen TT, Fenton JW, Bahou WF, Aviv A. Plasmin-platelet interaction involves cleavage of functional thrombin receptor. Am J Physiol Cell Physiol 1996; 271:C54–C60.
Wu J, Heemskerk JWM, Baaten CCFMJ. Platelet membrane receptor proteolysis: implications for platelet function. Front Cardiovasc Med 2021; 7:608391.
Schafer AI, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985; 75:456–461.
Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985; 65:32–40.
Pielsticker C, Brodde MF, Raum L, Jurk K, Kehrel BE. Plasmin-induced activation of human platelets is modulated by thrombospondin-1, bona fide misfolded proteins and thiol isomerases. IJMS 2020; 21:8851.
Quinton TM, Kim S, Derian CK, Jin J, Kunapuli SP. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 2004; 279:18434–18439.
Hur WS, Mazinani N, Lu XJD, Britton HM, Byrnes JR, Wolberg AS, et al. Coagulation factor XIIIa is inactivated by plasmin. Blood 2015; 126:2329–2337.
Samis JA, Ramsey GD, Walker JB, Nesheim ME, Giles AR. Proteolytic processing of human coagulation factor IX by plasmin. Blood 2000; 95:943–951.
Lorand L. Factor XIII and the clotting of fibrinogen: from basic research to medicine. J Thromb Haemost 2005; 3:1337–1348.
Hoover-Plow J. Does plasmin have anticoagulant activity? Vasc Health Risk Manag 2010; 6:199–205.
Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 2003; 101:3002–3007.
Brophy TM, Ward SE, McGimsey TR, Schneppenheim S, Drakeford C, O'Sullivan JM, et al. Plasmin cleaves von Willebrand factor at K1491-R1492 in the A1-A2 linker region in a shear- and glycan-dependent manner in vitro. ATVB 2017; 37:845–855.
Beckman JD, Holle LA, Wolberg AS. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking. J Thromb Haemost 2018; 16:131–141.
Xue Y, Bodin C, Olsson K. Crystal structure of the native plasminogen reveals an activation-resistant compact conformation. J Thromb Haemost 2012; 10:1385–1396.
Hunt J, Petteway S, Scuderi P, Novokhatny V. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin. Thromb Haemost 2008; 100:413–419.
Verhamme P, Jerome M, Goossens G, Devis J, Maleux G, Stas M. A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis. J Thromb Thrombolysis 2009; 28:477–481.
Putelli A, Kiefer JD, Zadory M, Matasci M, Neri D. A fibrin-specific monoclonal antibody from a designed phage display library inhibits clot formation and localizes to tumors in vivo. J Mol Biol 2014; 426:3606–3618.
Loike JD, Sodeik B, Cao L, Leucona S, Weitz JI, Detmers PA, et al. CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. Proc Natl Acad Sci U S A 1991; 88:1044–1048.
Ozeri V, Tovi A, Burstein I, Natanson-Yaron S, Caparon MG, Yamada KM, et al. A two-domain mechanism for Group A streptococcal adherence through protein F to the extracellular matrix. EMBO J 1996; 15:989–998.
Hassan MdM, Sharmin S, Kim H-J, Hong S-T. Identification and characterization of plasmin-independent thrombolytic enzymes. Circ Res 2021; 128:386–400.
Kline JA, Alves NJ, Beam DM. Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis. US202016792950; 2021-12-28.
Chen K, Wang Y, Liang H, Xia S, Liang W, Kong J, et al. Intrinsic Biotaxi solution based on blood cell membrane cloaking enables Fullerenol thrombolysis In Vivo . ACS Appl Mater Interfaces 2020; 12:14958–14970.
Altaf F, Wu S, Kasim V. Role of fibrinolytic enzymes in anti-thrombosis therapy. Front Mol Biosci 2021; 8:680397.